← All Novavax INC filings

Novavax INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
NVAX
Novavax INC
10-K: Novavax Swings to Profit in 2025 Amid Strategic Shifts
Novavax reported a significant financial turnaround in 2025, achieving net income of $440.3 million, driven by strategic partnership milestones and cost reductions, while securing new collaborations for its Matrix-M adjuvant.
NASDAQ
NVAX
Novavax INC
10-K: Novavax Reports 2024 Results, Highlights Sanofi Partnership and Pipeline Progress
Novavax's 2024 10-K filing details financial results, strategic shifts including a major Sanofi partnership, and ongoing development of its vaccine pipeline.
NASDAQ
NVAX
Novavax INC
10-K: Novavax Outlines Securities and Corporate Structure in 10-K Filing
Novavax's 10-K filing details the company's common stock, preferred stock, and various corporate governance provisions as of December 31, 2023.